Every day, ImmunoHeal rapidly diagnoses life-threatening infections and superbugs specifically
and accurately. Doctors use the powerful clinical
evidence from Hectoplex to save lives by treating
patients early, and with precision, while reducing
drugs and total cost.
The Hectoplex platform creates a decision support
system for antimicrobial therapy, and provides
extraordinary insights into the aetiology, prevalence
and epidemiology of infectious disease.
Technology and Science
The Hectoplex molecular diagnostics platform
comprises over 20 syndromic panels that precisely
mirror clinicians’ workflow and diagnostic challenges.
Hectoplex is built upon a robust, market-tested
chemistry. It has saved over 20,000 lives by
diagnosing critical infections in a few hours instead
of three days, and by covering the 85% of patients
who get no results from microbial cultures.
AI-driven infectious
disease prediction
Hectoplex already generates deep data on
infections that is transforming clinical practices.
As we build the future Hectoplex Ultra-Rapid
test platform, ImmunoHeal will create unparalleled
mapping, tracking and predictive tools for
infectious disease.
Innovation Advantage
A clinically validated proprietary library of over 400 biomarkers covering 68 pathogens and
18 antimicrobial resistance genes.
21 comprehensive panels for systemic, neurological and ophthalmic infections.
The world’s largest single panel for anti-microbial resistance.
Direct and verifiable evidence that pathogenic DNA or RNA is present in patient samples.
Evidence of secondary and polymicrobial infections.
High sensitivity and specificity rule out infections where other clinical assessments are inconclusive.
Targeted therapy
Proprietary and Unique
Precise solutions
Our Team
A seasoned team driving an empowering culture of innovation. Our Board and Advisors are well recognised industry, scientific and management leaders
Krish G. Krishnan
CEO
Dr. Ravi Kumar Banda
Scientific Adviser
Guy Beckerlegge
COO
Cancer and cardiovascular diseases get more attention
worldwide, but infectious diseases cause more
deaths every year (>11.0 million)
Social Impact
By democratising diagnoses and infectious
disease data, we impact every stratum of society
across vast geographies.
The socio-economic costs (GDP loss) from
antimicrobial resistance (AMR) will jump from
$200 billion in 2020 to nearly $2 trillion by 2030
from “The Review on Antimicrobial Resistance 2016”,
ed. Jim O’Neill – HM Government and Wellcome Trust
The economic impact of growing antimicrobial
resistance (AMR) makes it the greatest global
health threat in the coming decade.
Flexibility and Speed
The Hectoplex Acute Respiratory Infection Syndrome (ARIS) Panel
The novel coronavirus SARS-CoV-2 and COVID-19, the disease it causes, continue to pose a
global pandemic threat. In response, ImmunoHeal mobilised rapidly, and within six weeks
offers what the world will actually need during the current phase of the outbreak: a
comprehensive respiratory virus panel.
In 7 hours, the Hectoplex ARIS Panel
accurately identifies and distinguishes between
SARS-CoV-2, other CoVs, influenza and other
respiratory viruses.As COVID-19 spreads, the ARIS
panel allows public health officials to decide on the right way to deal with individuals who
share a narrow cluster of symptoms.
.svg)
